Roche’s oral GLP-1 receptor agonist CT-996 has weight loss of -6.1% within four weeks
Roche has reported positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational,...
top of page
Browse by category
Search
Carmot’s CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetes
Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for...
Browse by tag
bottom of page